FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1485191699> ?p ?o ?g. }

• W1485191699 endingPage "227" @default.
• W1485191699 startingPage "217" @default.
• W1485191699 abstract "Atherosclerotic peripheral arterial disease is associated with an increased risk of myocardial infarction, stroke, and death from cardiovascular causes. Antiplatelet drugs reduce this risk, but the role of oral anticoagulant agents in the prevention of cardiovascular complications in patients with peripheral arterial disease is unclear.We assigned patients with peripheral arterial disease to combination therapy with an antiplatelet agent and an oral anticoagulant agent (target international normalized ratio [INR], 2.0 to 3.0) or to antiplatelet therapy alone. The first coprimary outcome was myocardial infarction, stroke, or death from cardiovascular causes; the second coprimary outcome was myocardial infarction, stroke, severe ischemia of the peripheral or coronary arteries leading to urgent intervention, or death from cardiovascular causes.A total of 2161 patients were randomly assigned to therapy. The mean follow-up time was 35 months. Myocardial infarction, stroke, or death from cardiovascular causes occurred in 132 of 1080 patients receiving combination therapy (12.2%) and in 144 of 1081 patients receiving antiplatelet therapy alone (13.3%) (relative risk, 0.92; 95% confidence interval [CI], 0.73 to 1.16; P=0.48). Myocardial infarction, stroke, severe ischemia, or death from cardiovascular causes occurred in 172 patients receiving combination therapy (15.9%) as compared with 188 patients receiving antiplatelet therapy alone (17.4%) (relative risk, 0.91; 95% CI, 0.74 to 1.12; P=0.37). Life-threatening bleeding occurred in 43 patients receiving combination therapy (4.0%) as compared with 13 patients receiving antiplatelet therapy alone (1.2%) (relative risk, 3.41; 95% CI, 1.84 to 6.35; P<0.001).In patients with peripheral arterial disease, the combination of an oral anticoagulant and antiplatelet therapy was not more effective than antiplatelet therapy alone in preventing major cardiovascular complications and was associated with an increase in life-threatening bleeding. (ClinicalTrials.gov number, NCT00125671 [ClinicalTrials.gov].)." @default.
• W1485191699 created "2016-06-24" @default.
• W1485191699 creator A5007198463 @default.
• W1485191699 creator A5016851305 @default.
• W1485191699 creator A5018419311 @default.
• W1485191699 creator A5021591848 @default.
• W1485191699 creator A5033105398 @default.
• W1485191699 creator A5036545933 @default.
• W1485191699 creator A5041291525 @default.
• W1485191699 creator A5045634872 @default.
• W1485191699 creator A5045775390 @default.
• W1485191699 creator A5047726859 @default.
• W1485191699 creator A5056775216 @default.
• W1485191699 creator A5058205892 @default.
• W1485191699 creator A5084746877 @default.
• W1485191699 date "2007-07-19" @default.
• W1485191699 modified "2023-10-16" @default.
• W1485191699 title "Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease" @default.
• W1485191699 cites W108084996 @default.
• W1485191699 cites W1586488555 @default.
• W1485191699 cites W1981674111 @default.
• W1485191699 cites W1991549653 @default.
• W1485191699 cites W2017836681 @default.
• W1485191699 cites W2024352468 @default.
• W1485191699 cites W2046051565 @default.
• W1485191699 cites W2059885795 @default.
• W1485191699 cites W2113989522 @default.
• W1485191699 cites W2125648462 @default.
• W1485191699 cites W2141610267 @default.
• W1485191699 cites W2170421103 @default.
• W1485191699 cites W2315630371 @default.
• W1485191699 cites W2426190701 @default.
• W1485191699 cites W2597867456 @default.
• W1485191699 cites W311320695 @default.
• W1485191699 cites W4236878386 @default.
• W1485191699 cites W4237556338 @default.
• W1485191699 doi "https://doi.org/10.1056/nejmoa065959" @default.
• W1485191699 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17634457" @default.
• W1485191699 hasPublicationYear "2007" @default.
• W1485191699 type Work @default.
• W1485191699 sameAs 1485191699 @default.
• W1485191699 citedByCount "361" @default.
• W1485191699 countsByYear W14851916992012 @default.
• W1485191699 countsByYear W14851916992013 @default.
• W1485191699 countsByYear W14851916992014 @default.
• W1485191699 countsByYear W14851916992015 @default.
• W1485191699 countsByYear W14851916992016 @default.
• W1485191699 countsByYear W14851916992017 @default.
• W1485191699 countsByYear W14851916992018 @default.
• W1485191699 countsByYear W14851916992019 @default.
• W1485191699 countsByYear W14851916992020 @default.
• W1485191699 countsByYear W14851916992021 @default.
• W1485191699 countsByYear W14851916992022 @default.
• W1485191699 countsByYear W14851916992023 @default.
• W1485191699 crossrefType "journal-article" @default.
• W1485191699 hasAuthorship W1485191699A5007198463 @default.
• W1485191699 hasAuthorship W1485191699A5016851305 @default.
• W1485191699 hasAuthorship W1485191699A5018419311 @default.
• W1485191699 hasAuthorship W1485191699A5021591848 @default.
• W1485191699 hasAuthorship W1485191699A5033105398 @default.
• W1485191699 hasAuthorship W1485191699A5036545933 @default.
• W1485191699 hasAuthorship W1485191699A5041291525 @default.
• W1485191699 hasAuthorship W1485191699A5045634872 @default.
• W1485191699 hasAuthorship W1485191699A5045775390 @default.
• W1485191699 hasAuthorship W1485191699A5047726859 @default.
• W1485191699 hasAuthorship W1485191699A5056775216 @default.
• W1485191699 hasAuthorship W1485191699A5058205892 @default.
• W1485191699 hasAuthorship W1485191699A5084746877 @default.
• W1485191699 hasBestOaLocation W14851916991 @default.
• W1485191699 hasConcept C126322002 @default.
• W1485191699 hasConcept C127413603 @default.
• W1485191699 hasConcept C164705383 @default.
• W1485191699 hasConcept C2777466421 @default.
• W1485191699 hasConcept C2777798775 @default.
• W1485191699 hasConcept C2778213512 @default.
• W1485191699 hasConcept C2780645631 @default.
• W1485191699 hasConcept C44249647 @default.
• W1485191699 hasConcept C500558357 @default.
• W1485191699 hasConcept C71924100 @default.
• W1485191699 hasConcept C78519656 @default.
• W1485191699 hasConcept C82789193 @default.
• W1485191699 hasConceptScore W1485191699C126322002 @default.
• W1485191699 hasConceptScore W1485191699C127413603 @default.
• W1485191699 hasConceptScore W1485191699C164705383 @default.
• W1485191699 hasConceptScore W1485191699C2777466421 @default.
• W1485191699 hasConceptScore W1485191699C2777798775 @default.
• W1485191699 hasConceptScore W1485191699C2778213512 @default.
• W1485191699 hasConceptScore W1485191699C2780645631 @default.
• W1485191699 hasConceptScore W1485191699C44249647 @default.
• W1485191699 hasConceptScore W1485191699C500558357 @default.
• W1485191699 hasConceptScore W1485191699C71924100 @default.
• W1485191699 hasConceptScore W1485191699C78519656 @default.
• W1485191699 hasConceptScore W1485191699C82789193 @default.
• W1485191699 hasIssue "3" @default.
• W1485191699 hasLocation W14851916991 @default.
• W1485191699 hasLocation W14851916992 @default.
• W1485191699 hasLocation W14851916993 @default.
• W1485191699 hasOpenAccess W1485191699 @default.

• next